A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
A Pan-Cancer Analysis Reveals CLEC5A as a Biomarker for Cancer Immunity and Prognosis.
复制标题
泛癌症分析揭示 CLEC5A 作为癌症免疫和预后的生物标志物
DOI：
10.3389/fimmu.2022.831542
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
CLEC5A是C型凝集素超家族的成员。它可以激活巨噬细胞，导致一系列免疫炎症反应。先前的研究揭示了CLEC5A在感染和炎症性疾病中的作用。我们通过GSCALite、cBioPortal和Timer 2.0平台或软件从癌症基因组图谱(TCGA)数据库、基因类型-组织表达(GTEx)数据库和其他综合数据库获取和分析数据。单细胞测序分析用于量化几种类型癌症的肿瘤微环境。CLEC5A在一些癌症类型中有不同的表达，其中过度表达伴随着患者的低总存活率。DNA甲基化主要与CLEC5A表达呈负相关。此外，CLEC5A与免疫渗透呈正相关，包括巨噬细胞、肿瘤相关成纤维细胞(CAF)和调节性T细胞(Tregs)。免疫检查点基因与CLEC5A在多种癌症中的表达显著相关。此外，在几种癌症中，CLEC5A的表达与错配修复(MMR)相关。肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)和新抗原与几种癌症中CLEC5A的表达呈正相关。此外，肿瘤中的CLEC5A与信号转导、免疫系统、EMT和细胞凋亡过程有关。药敏分析筛选出与CLEC5A表达相关的潜在治疗药物，包括FR-180204、替沃扎尼、OSI-930、利尼法尼、AC220、VNLG/124、贝沙罗汀、甲基丁二酸奥乙酰克辛、那西拉辛、软霉素B、PHA-793887、LRRK2-IN-1和CR-1-31B。与正常组织相比，CLEC5A在多种肿瘤中高表达，高表达预示着患者预后不良和免疫浸润。CLEC5A是多种癌症的潜在预后生物标志物，也是抗肿瘤治疗的靶点。
CLEC5A is a member of the C-type lectin superfamily. It can activate macrophages and lead to a series of immune-inflammation reactions. Previous studies reveal the role of CLEC5A in infection and inflammation diseases. We acquire and analyze data from The Cancer Genome Atlas (TCGA) database, Genotype-Tissue Expression (GTEx) database, and other comprehensive databases via GSCALite, cBioPortal, and TIMER 2.0 platforms or software. Single-cell sequencing analysis was performed for quantifying the tumor microenvironment of several types of cancers. CLEC5A is differentially expressed in a few cancer types, of which overexpression accompanies low overall survival of patients. DNA methylation mainly negatively correlates with CLEC5A expression. Moreover, CLEC5A is positively related to immune infiltration, including macrophages, cancer-associated fibroblasts (CAFs), and regulatory T cells (Tregs). Immune checkpoint genes are significantly associated with CLEC5A expression in diverse cancers. In addition, CLEC5A expression correlates with mismatch repair (MMR) in several cancers. Tumor mutation burden (TMB), microsatellite instability (MSI), and neoantigens show a positive association with CLEC5A expression in several cancers. Furthermore, CLEC5A in cancer correlates with signal transduction, the immune system, EMT, and apoptosis process. The drug sensitivity analysis screens out potential therapeutic agents associated with CLEC5A expression, including FR-180204, Tivozanib, OSI-930, Linifanib, AC220, VNLG/124, Bexarotene, omacetaxine mepesuccinate, narciclasine, leptomycin B, PHA-793887, LRRK2-IN-1, and CR-1-31B. CLEC5A overexpresses in multiple cancers in contrast to normal tissues, and high CLEC5A expression predicts poor prognosis of patients and immune infiltration. CLEC5A is a potential prognostic biomarker of diverse cancers and a target for anti-tumor therapy.
登录
查看更多内容
CLEC5A 是针对李斯特菌感染的先天免疫的关键受体。
影响因子：
16.6
作者：
Chen ST;Li FJ;Hsu TY;Liang SM;Yeh YC;Liao WY;Chou TY;Chen NJ;Hsiao M;Yang WB;Hsieh SL
通讯作者：
Hsieh SL
影响因子：
3.7
作者：
Chen DY;Yao L;Chen YM;Lin CC;Huang KC;Chen ST;Lan JL;Hsieh SL
通讯作者：
Hsieh SL
影响因子：
64.8
作者：
Ghandi, Mahmoud;Huang, Franklin W.;Sellers, William R.
通讯作者：
Sellers, William R.
影响因子：
6.6
作者：
Manoochehri, Mehdi;Wu, Yenan;Bauer, Andrea S.
通讯作者：
Bauer, Andrea S.
NFE2L2 是一种潜在的预后生物标志物，与脑低级别胶质瘤的免疫浸润相关：一项泛癌症分析。
影响因子：
--
作者：
Ju Q;Li X;Zhang H;Yan S;Li Y;Zhao Y
通讯作者：
Zhao Y